卡格列净对CANVAS试验中血浆生物标志物TNFR-1、TNFR-2和KIM-1的影响
在CANVAS试验中,3523/4330(81.4%)的2型糖尿病参与者有基线样本。卡格列净较安慰剂降低KIM-1及轻度降低TNFR-1、TNFR-2;卡格列净治疗1年时TNFR-1和TNFR-2的早期下降与肾脏结局风险降低独立相关。
要点
- 卡格列净降低KIM-1幅度较大,对TNFR-1和TNFR-2仅有轻度降低。
- 基线TNFR-1、TNFR-2和KIM-1翻倍均与肾脏结局风险升高相关。
- 卡格列净治疗1年时TNFR-1和TNFR-2下降与肾脏结局风险降低独立相关。
核心结论
- 在CANVAS的2型糖尿病患者中,卡格列净较安慰剂降低KIM-1并轻度降低TNFR-1和TNFR-2。
- 卡格列净治疗早期TNFR-1和TNFR-2的下降与肾脏疾病进展风险降低独立相关。
- TNFR-1和TNFR-2有潜力作为卡格列净药效学反应标志物。
研究设计与样本
- CANVAS研究样本分析,在基线及第1、3、6年用免疫分析法检测生物标志物。
- 采用重复测量混合效应模型评估卡格列净vs安慰剂对生物标志物的影响。
- 用多变量校正Cox回归评估基线水平及早期变化(基线至第1年)与肾脏结局的关联。
- 3523/4330(81.4%)的CANVAS参与者有基线可用样本。
主要发现
- 基线TNFR-1每翻倍与肾脏结局风险升高相关,HR 3.7(95% CI 2.3, 6.1;p < 0.01)。
- 基线TNFR-2每翻倍与肾脏结局风险升高相关,HR 2.7(95% CI 2.0, 3.6;p < 0.01)。
- 基线KIM-1每翻倍与肾脏结局风险升高相关,HR 1.5(95% CI 1.2, 1.8;p < 0.01)。
- 随访期间卡格列净vs安慰剂TNFR-1差异为2.8%(95% CI 3.4%, 1.3%;p < 0.01),TNFR-2差异为1.9%(95% CI 3.5%, 0.2%;p = 0.03),KIM-1差异为26.7%(95% CI 30.7%, 22.7%;p < 0.01)。
- 卡格列净组第1年TNFR-1每降低10%与肾脏结局风险降低相关(HR 0.8 [95% CI 0.7, 1.0;p = 0.02]),TNFR-2每降低10%亦相关(HR 0.9 [95% CI 0.9, 1.0;p < 0.01])。
临床怎么用
- 对2型糖尿病患者使用卡格列净时,可关注TNFR-1和TNFR-2早期下降作为肾脏反应标志物的潜在价值。
- KIM-1在卡格列净治疗后下降幅度较大,可作为肾脏保护效应的参考指标。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: Higher plasma concentrations of tumour necrosis factor receptor (TNFR)-1, TNFR-2 and kidney injury molecule-1 (KIM-1) have been found to be associated with higher risk of kidney failure in individuals with type 2 diabetes in previous studies. Whether drugs can reduce these biomarkers is not well established. We measured these biomarkers in samples of the CANVAS study and examined the effect of the sodium-glucose cotransporter 2 inhibitor canagliflozin on these biomarkers and assessed whether the early change in these biomarkers predict cardiovascular and kidney outcomes in individuals with type 2 diabetes in the CANagliflozin cardioVascular Assessment Study (CANVAS). METHODS: Biomarkers were measured with immunoassays (proprietary multiplex assay performed by RenalytixAI, New York, NY, USA) at baseline and years 1, 3 and 6. Mixed-effects models for repeated measures assessed the effect of canagliflozin vs placebo on the biomarkers. Associations of baseline levels and the early change (baseline to year 1) for each biomarker with the kidney outcome were assessed using multivariable-adjusted Cox regression. RESULTS: In total, 3523/4330 (81.4%) of the CANVAS participants had available samples at baseline. Each doubling in baseline TNFR-1, TNFR-2 and KIM-1 was associated with a higher risk of kidney outcomes, with corresponding HRs of 3.7 (95% CI 2.3, 6.1; p < 0.01), 2.7 (95% CI 2.0, 3.6; p < 0.01) and 1.5 (95% CI 1.2, 1.8; p < 0.01), respectively. Canagliflozin reduced the level of the plasma biomarkers with differences in TNFR-1, TNFR-2 and KIM-1 between canagliflozin and placebo during follow-up of 2.8% (95% CI 3.4%, 1.3%; p < 0.01), 1.9% (95% CI 3.5%, 0.2%; p = 0.03) and 26.7% (95% CI 30.7%, 22.7%; p < 0.01), respectively. Within the canagliflozin treatment group, each 10% reduction in TNFR-1 and TNFR-2 at year 1 was associated with a lower risk of the kidney outcome (HR 0.8 [95% CI 0.7, 1.0; p = 0.02] and 0.9 [95% CI 0.9, 1.0; p < 0.01] respectively), independent of other patient characteristics. The baseline and 1 year change in biomarkers did not associate with cardiovascular or heart failure outcomes. CONCLUSIONS/INTERPRETATION: Canagliflozin decreased KIM-1 and modestly reduced TNFR-1 and TNFR-2 compared with placebo in individuals with type 2 diabetes in CANVAS. Early decreases in TNFR-1 and TNFR-2 during canagliflozin treatment were independently associated with a lower risk of kidney disease progression, suggesting that TNFR-1 and TNFR-2 have the potential to be pharmacodynamic markers of response to canagliflozin.
引用
- Sen T, Li J, Neuen BL, et al. Effects of the SGLT2 inhibitor canagliflozin on plasma biomarkers TNFR-1, TNFR-2 and KIM-1 in the CANVAS trial. Diabetologia. 2021. PMID: 34415356. doi:10.1007/s00125-021-05512-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。